a Cancer and Translational Research Lab, Dr. D.Y. Patil Biotechnology & Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth , Pune , Maharashtra , India.
Cancer Biol Ther. 2018 Jan 2;19(1):3-12. doi: 10.1080/15384047.2017.1394538. Epub 2017 Dec 8.
The microenvironment in which cancer resides plays an important role in regulating cancer survival, progression, malignancy and drug resistance. Tumor microenvironment (TME) consists of heterogeneous number and types of cellular and non-cellular components that vary in relation to tumor phenotype and genotype. In recent, non-cellular secreted components of microenvironmental heterogeneity have been suggested to contain various growth factors, cytokines, RNA, DNA, metabolites, structural matrix and matricellular proteins. These non-cellular components have been indicated to orchestrate numerous ways to support cancer survival and progression by providing metabolites, energy, growth signals, evading immune surveillance, drug resistance environment, metastatic and angiogenesis cues. Thus, switching action from pro-cancer to anti-cancer activities of these secreted components of TME has been considered as a new avenue in cancer therapeutics and drug resistance. In this report, we summarize the recent pre-clinical and clinical evidences to emphasize the importance of non-cellular components of TME in achieving precision therapeutics and biomarker study.
肿瘤微环境在调节癌症的存活、进展、恶性程度和耐药性方面起着重要作用。肿瘤微环境(TME)由异质性数量和类型的细胞和非细胞成分组成,这些成分与肿瘤表型和基因型有关。最近,有人提出微环境异质性的非细胞分泌成分中含有各种生长因子、细胞因子、RNA、DNA、代谢物、结构基质和基质细胞蛋白。这些非细胞成分通过提供代谢物、能量、生长信号、逃避免疫监视、耐药环境、转移和血管生成线索,以多种方式协调支持癌症存活和进展。因此,将 TME 分泌成分的促癌作用转变为抗癌作用被认为是癌症治疗和耐药性研究的新途径。在本报告中,我们总结了最近的临床前和临床证据,强调了 TME 中非细胞成分在实现精准治疗和生物标志物研究中的重要性。